C. difficile infections generate an annual economic burden of more than $1 billion. Traditional first line treatment includes antibiotics. Researchers found FMT to be more cost-effective than metronidazole and fidaxomicin.
The researchers concluded that C. difficile infection treatment guidelines should consider recommending use of FMT at an earlier time.
More Articles on Gastroenterology:
6 Statistics on Colorectal Cancer Diagnosis & Mortality
2014 Outlook: 7 Issues for Gastroenterologists to Focus on This Year
5 Things to Know About Advances in Oral Treatment for Hepatitis C
